COVID-19 Updates: COVID-19 Resources » Vaccine Update » Updated Visitor Policy » What We're Doing to Keep You Safe »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
Trial ID or NCT#
Status
RECRUITING
Purpose
The purpose of this study is to evaluate whether extended prophylaxis with oral betrixaban can prevent blood clots in the leg and lung that sometime occur in patients hospitalized for an acute medical illness and to compare these results with standard of care enoxaparin. The safety of betrixaban will also be studied.
Official Title
(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients
Eligibility Criteria
- - men and non-pregnant, non-breastfeeding women - anticipated to be severely immobilized for at least 24 hours after randomization - hospitalized with one of the following - congestive heart failure - acute respiratory failure, - acute infection without septic shock, - acute rheumatic disorders - acute ischemic stroke with lower extremity hemiparesis or hemi paralysis
- - a condition requiring prolonged anticoagulation or anti-platelets - active bleeding or at high risk of bleeding - contraindication to anticoagulant therapy - general conditions in which subjects are not suitable to participate in the study
Investigator(s)
Contact us to find out if this trial is right for you.
CONTACT
APEX Study Clinical Trial Contact
(855) 256-7070
View on ClinicalTrials.gov
About this Clinical Trial
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
Your Message Will Go To
APEX Study Clinical Trial Contact855-256-7070